Opko Health Inc (OPK) has risen sharply, recording gains of 2.37% in the past 4 weeks. However, the stock has corrected -0.2% in the past 1 week, providing a good buying opportunity on dips. Opko Health Inc (OPK) : During the past 4 weeks, traders have been relatively bearish on Opko Health Inc (OPK), hence the stock is down -0.96% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.13% relative to the S&P 500.
The stock has recorded a 20-day Moving Average of 1.11% and the 50-Day Moving Average is 1.57%. Opko Health, Inc. has dropped 7.44% during the last 3-month period . Year-to-Date the stock performance stands at -1%.
Opko Health Inc (NYSE:OPK): stock turned positive on Friday. Though the stock opened at $9.89, the bulls momentum made the stock top out at $9.96 level for the day. The stock recorded a low of $9.76 and closed the trading day at $9.95, in the green by 0.61%. The total traded volume for the day was 2,153,115. The stock had closed at $9.89 in the previous days trading.
Also, Equity analysts at the Brokerage firm Deutsche Bank maintains its rating on Opko Health Inc (NYSE:OPK). The rating major has initiated the coverage with hold rating on the shares. The Analysts at Deutsche Bank lowers the price target from $11 per share to $10 per share. The rating by the firm was issued on June 16, 2016.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.